Tags Posts tagged with "2017 Marijuana Stocks"

2017 Marijuana Stocks

0 903
 

Marijuana Stocks Connect The Dots *Update*

 

We at Marijuana Stocks wanted to give an update to our Connect the Dots report we put out yesterday, but first we need to give you some very important information!

 

 


Click Here Now To Read Full Update on (KWFLF) (CBW.V)


 

Three More Canadian Marijuana Stocks You Should Know About

Canadian cannabis stocks continue to attract new investors, new institutional capital, and new strategic partners as legal recreational cannabis will help the industry see incremental growth for years to come.Although this week is a short week due to the Monday’s holiday, Canadian firms continue to report significant company developments and we want to highlight three stories that investors need to be aware of.

 


Click Here Now To Read Full Article


 

Tetra Bio-Pharma Inc. (TBPMF) Signs Definitive Agreement for Two Products

 

Tetra Bio-Pharma Inc. (“Tetra” or the “Company“) (CSE:TBP)(CSE:TBP.CN)(CNSX:TBP)(OTCQB:TBPMF), announced today it has signed a definitive agreement with Panag Pharma Inc. for the development and commercialization of novel cannabinoid based formulations for the treatment of pain and inflammation. Combined total market potential of both products in the USA in 2014 is estimated over US$5.5 billion. The recent press release on May 17th for the filing of a patent in ocular disease combined with the patents from Panag in the ocular space make this agreement very lucrative.

 

 


Click Here Now To Read Full PR on (TBPMF)


 

marijuana-stocks-canadian-cannabis

Canadian cannabis stocks continue to attract new investors, new institutional capital, and new strategic partners as legal recreational cannabis will help the industry see incremental growth for years to come.

Although this week is a short week due to the Monday’s holiday, Canadian firms continue to report significant company developments and we want to highlight three stories that investors need to be aware of. 

Tetra Enters Strategic Partnership and Changes its U.S. Symbol

Tetra Bio-Pharma (TBP.CN: CSE) (TBPMF) signed a definitive agreement with Panag Pharma for the development and commercialization of novel cannabinoid based formulations for the treatment of pain and inflammation. This partnership combined with the company’s patent filing last week could make this a profitable relationship. Tetra is focused on generating revenue in 2017 by launching retail products via its partnership with Panag.

Under the agreement, Tetra will have the exclusive right to sell the ocular and topical drug products in North America with right of first negotiation for international markets. Tetra will also have a right of first negotiation for future cannabinoid-based products.

Tetra will work with Panag’s team to ensure a rapid and successful process leading to marketing authorization. Panag will continue to develop new novel products for unmet medical need and Tetra will focus on commercializing these products.

Panag has developed potential new cannabinoid-based therapies for ocular and topical anti-inflammatory and pain markets. The company also developed a cannabinoid topical drug product for the local treatment of pain and inflammation.

Tetra also issued a corporate update and highlighted the following:

  • Changed its U.S. OTCQB symbol to TBPMF
  • Issued 501,800 new shares as part as of a service agreement from June 20, 2016.
  • Issued 250,000 new shares as part of a service agreement with MAPH Enterprises to broaden U.S. investor awareness.

 Canadian Biotech Firm to Raise $5+ Million

InMed Pharmaceuticals (IN.CN: CSE) (IMLFF) entered an underwriting agreement with a syndicate of underwriters led by Canaccord Genuity and includes Eight Capital along with Roth Capital Partners (placement agent). The underwriters agreed to purchase, on an underwritten basis, 11,120,000 units at $0.45 each for $5 million in aggregate gross proceeds.

InMed plans to use the proceeds for the following reasons: 1) To support the continued research and development of INM-750 for the treatment of Epidermolysis Bullosa, 2) To further develop the company’s other research and development programs including its biosynthesis assets, 3) For general and administrative expenses, and 4) To fund working capital.

Each unit is comprised of one common share and one-half share purchase warrant. The warrant has an exercise price of $0.65 and will be exercisable for a period of 24 months following the closing date. The offering is expected to close by May 30th. InMed granted the underwriters the option to purchase up to 1,668,000 additional units at $0.45 each for a period of up to 30 days after the closing date. If this option is exercised in full, the company will generate $5.75 million in aggregate gross proceeds.

Marapharm Looks to Enter Nevada’s Recreational Market

Yesterday, Marapharm Ventures (MDM: CSE) (MRPHF) took a significant step forward in its plans to take advantage of the Nevada recreational cannabis market. Marapharm acquired two fully equipped buildings that meet Nevada’s state licensing requirements and the company must move quick if they want to take advantage of this huge opportunity.

Marapharm’s buildings were inspected and given pre-approval for cultivation and processing. If the company can be approved before May 31st and conduct a taxable transaction, it will be allowed to apply for licensing under the state’s recreational program.

Nevada’s department of taxation is currently accepting applications for recreational cultivation, production, lab and retail store licenses, from existing Nevada marijuana establishments that hold valid registration certificates.

Marapharm has 300,000 square feet of medical marijuana licenses for its land and facilities in Washington state and Nevada. About three years ago, Marapharm applied in Canada to Health Canada and the application is currently in the in-depth screening process. In September, Health Canada contacted Marapharm with a provision to amend its application to allow for the new regulations, ACMPR.

We are on the sidelines but think this is a story and a stock investors should keep an eye on!

 

Author: Michael Berger

 


 

Disclaimer: Pursuant to an agreement between MAPH and InMedPharmaceuticals., we were hired for a period beginning February 24 2017 and ending April 24, 2017 to publicly disseminate information about (IMLFF) including on the Website and other media including Facebook and Twitter. We are being paid $40,000 (CASH) for and were paid “250,000” shares of restricted common shares of InMed Pharmaceuticals.We may buy or sell additional shares of (IMLFF) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Pursuant to an agreement between MAPH and Tetra Bio-Pharma, we were hired for a period of 90 days to publicly disseminate information about (TBPMF) including on the Website and other media including Facebook and Twitter. We are being paid $75,000 (CASH) for and were paid 250,000 restricted common shares of Tetra Bio-Pharma. We may buy or sell additional shares of (TBPMF) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information.

0 367
marijuana-stocks-cannabis-wheaton

Mr. Chuck Rifici reports

CANNABIS WHEATON ANNOUNCES PRIVATE PLACEMENT OF SPECIAL WARRANTS AND CONVERTIBLE DEBENTURE UNITS

Cannabis Wheaton Income Corp. (KWFLF) (CBW.V) has engaged a syndicate of agents co-led by Eight Capital and Canaccord Genuity Corp. to sell, on a best efforts, private placement basis, special warrants and convertible debenture units (as described below) of the company, for gross proceeds of up to $50-million.

The Company has agreed to grant the Agents an over-allotment option to offer up to that number of additional Special Warrants and/or Convertible Debenture Units as is equal to 15% of the number sold in the Offering, on the same terms and conditions as the Offering, increasing the size of the Offering to a maximum of $57,500,000 in aggregate gross proceeds. The over-allotment option may be exercised in whole or in part on or before 48 hours prior to the closing of the Offering, which is expected to occur on or about June 21, 2017 (the “Closing Date”).

The net proceeds from the Offering will primarily be used for general corporate purposes, including but not limited to, the financing of the Company’s streaming partners pursuant to certain of the Company’s streaming agreements, and for general and administrative expenses.

The Offering will consist of “Special Warrants” and “Convertible Debenture Units” as follows.

Special Warrants

Each Special Warrant will be offered at a price of $1.15 per Special Warrant for gross proceeds of up to $25,000,000 (the “Special Warrant Offering”). Each Special Warrant will be automatically exercised (without any further action by the holder or payment of any further consideration and subject to customary anti-dilution adjustments) into one Unit (as defined below) of the Company on the date (the “Automatic Exercise Date”) that is the earlier of: (i) the date that is three business days following the date on which the Company obtains a receipt from the applicable Canadian securities regulatory authorities (the “Securities Commissions”) for a (final) short form prospectus qualifying the distribution of the Units issuable upon exercise of the Special Warrants (the “Qualifying Prospectus”), and (ii) the date that is four months and one day after the Closing Date. Each Unit will consist of one common share (each a “Common Share”) and one common share purchase warrant of the Company (a “Warrant”). Each Warrant will (subject to acceleration and customary anti-dilution adjustments) entitle the holder thereof to purchase one Common Share, at any time on or prior to the date that is 24 months following the Closing Date, at an exercise price of $1.60 per share. The Company will use its commercially reasonable efforts to obtain a receipt from the Securities Commissions for the Qualifying Prospectus before the date that is four months and one day following the Closing Date; provided, however, that there is no assurance that a Qualifying Prospectus will be filed or that a receipt therefor will be issued by the Securities Commissions prior to the expiry of the statutory four month hold period.

Convertible Debenture Units

Each Convertible Debenture Unit will be offered at a price of $1,000 per Convertible Debenture Unit for gross proceeds of up to $25,000,000. Each Convertible Debenture Unit will consist of $1,000 principal amount of 6% senior unsecured convertible debentures (the “Convertible Debentures”) and 435 Common Share purchase warrants (the “CD Warrants”) of the Company. Each CD Warrant (subject to acceleration and customary anti-dilution adjustments) will be exercisable to acquire one Common Share at an exercise price of $1.60 per share for a period of 24 months following the Closing Date. Subject to the Company filing a Qualifying Prospectus (as described above), the Convertible Debentures, the CD Warrants and the Common Shares will be subject to the statutory four month hold period.

The Convertible Debentures will bear interest from the Closing Date at 6.0% per annum, calculated semi-annually in arrears on June 30 and December 31 of each year. The first interest payment will be made on June 30, 2018 and will consist of interest accrued from and including the Closing Date to June 30, 2018. The Convertible Debentures will mature on the date that is 24 months from the Closing Date (the “Maturity Date”).

The Convertible Debentures will be convertible into Common Shares at the option of the holder at any time prior to the close of business on the last business day immediately preceding the Maturity Date at a conversion price of $1.15 per Common Share (the “Conversion Price”), subject to adjustment in certain events. Holders converting their Convertible Debentures will receive accrued and unpaid interest thereon for the period from and including the date of the latest interest payment date to, but excluding, the date of conversion.

Beginning on the date that is four months and one day following the Closing Date, the Company may force the conversion of the principal amount of the then outstanding Convertible Debentures at the Conversion Price on not less than 30 days’ notice should the daily volume weighted average trading price of the Company’s Common Shares be greater than $2.30 for any 10 consecutive trading days on the TSX Venture Exchange (the “TSX-V”), or such other exchange as the Common Shares may then be trading (the “Trigger Event”). In addition, upon the occurrence of the Trigger Event, the Company may also accelerate the expiry date of the Warrants and CD Warrants on not less than 30 days’ notice.

Subject to a number of customary closing conditions (including the Company completing the Special Warrant Offering), the Company is pleased to announce that MMCAP International Inc. SPC (the “Lead Subscriber”) intends to subscribe for up to $20,000,000 aggregate principal amount of the Convertible Debenture Units.

Closing Conditions and Related Matters

The Offering is subject to a number of customary closing conditions, including TSX-V approval, negotiation of definitive closing documents, due diligence and the absence of a material adverse change.

As part of the Offering, directors, officers, and certain other shareholders, together representing approximately 55% of the issued and outstanding Common Shares on a fully diluted basis (prior to giving effect to the Offering), have agreed to enter into lock-up agreements in favour of the Agents restricting their ability to transfer their Common Shares and other securities of the Company convertible into Common Shares (collectively, the “Lock-Up Securities”) until the date that is 12 months following the Closing Date, provided that: (i) one-third of the Lock-Up Securities shall cease to be subject to the lock-up on the date that is 6 months and one day following the Closing Date; and (ii) a further one-third of the Lock-Up Securities shall cease to be subject to the lock-up on the date that is 9 months and one day following the Closing Date.

Representatives of the Co-Lead Agents hold an aggregate of 13,139,859 common shares and 13,139,859 common share purchase warrants of the Company, representing approximately 8.0% of the issued and outstanding common shares on a basic basis (8.5% of the outstanding common shares on a fully-diluted basis) as at the date hereof.

The Company also announces that it has filed an amended and restated annual information form containing additional disclosure relating to its updated investment strategy in the cannabis industry.

We seek Safe Harbor.

marijuana-stocks-canadian-cannabis-

The Canadian stock market was closed for Victoria Day yesterday and today, three marijuana stocks reported several significant developments. We have highlighted these developments below to help you focus on important trends sweeping the industry.

New Cannabis IPO to Raise $50+ Million

One of newest and most differentiated Canadian cannabis producers, Cannabis Wheaton (CBW.V: TSX Venture) (KWFLF) announced a $50 million private placement and engaged a syndicate of agents co-led by Eight Capital and Canaccord Genuity.

The firm is selling special warrants and convertible debenture units and will use the net proceeds for general corporate purposes, for the financing of its streaming partners pursuant its streaming agreements, and for general and administrative expenses.

Cannabis Wheaton is off to a great start after the company reported that MMCAP International Inc. SPC intends to subscribe for up to $20,000,000 of the offering. The offering is expected to occur on June 21st and the company granted the underwriters an over-allotment option which increases the offering to $57.5 million.

Cronos’ Breaks Ground on a Brand New 315,000 sq. ft. Facility

Today, Cronos Group’s (MJN.V: TSX Venture) (PRMCF) wholly-owned licensed producer, the Peace Naturals Project broke ground on a 315,000 sq. ft. expansion that includes a 286,000 sq. ft. production facility, a 28,000 sq. ft. greenhouse, and an additional 1,200 sq. ft. extraction lab.

Upon completion, the facility is expected to be the largest purpose-built indoor cannabis production facility in the world. The facility is expected to complete by November and fully operational by summer 2018. This expansion will bring Peace’s total estimated production capacity to 40,000 kg a year.

The facility is designed to GMP certification standards and will include:

  • An area for proprietary genetic breeding
  • Pharma lab for cannabinoid and terpene extraction, identification, and formulation
  • R&D space for analyzing metabolite enhancement and new lighting technologies
  • Tissue culture laboratory
  • Industrial-grade kitchen
  • Processing infrastructure that supports production from other facilities

Cronos is breaking ground on the greenhouse today and the facility will be used to collect data and implement advanced cultivation techniques that can be replicated at its other production facilities. The company’s extraction lab will augment capabilities in both purification and recombination of cannabinoid compounds to create innovative formulated products. The greenhouse and lab are expected by the end of the summer.

Aurora to Supply Resources to Support a Groundbreaking Legal Case

Today, the Canadians for Fair Access to Medical Marijuana (CFAMM) reported an investment by Aurora Cannabis (ACB.V) (ACBFF) that is of a different nature than its prior investments.

CFAMM announced that Aurora has committed financial and other resources to support Gordon Skinner’s defense in what might be a potentially precedent-setting medical cannabis insurance coverage case. CFAMM has been providing strategic support to Skinner and Aurora’s resources will ensure that Skinner can defend his case.

On January 30th, the Nova Scotia Human Rights Commission ruled that the Board of Trustees of the Canadian Elevator Industry Welfare Trust Fund committed discrimination by denying coverage for the medical cannabis Skinner uses to manage chronic pain and other conditions resulting from a work-related injury that left him permanently impaired. Following the decision, the Board of Trustees filed an appeal against Skinner and the Commission in the Nova Scotia Court of Appeal. The appeal has been set for October 2, 2017.

Founded in 2014, Canadians for Fair Access to Medical Marijuana (CFAMM) is a federal non-profit, patient-run organization dedicated to protecting and improving the rights of medical cannabis patients. CFAMM’s goal is to enable patients to obtain fair and safe access to medical cannabis with a special focus on affordability, including private and public insurance coverage.

We want to commend Aurora on its commitment to improving the cannabis industry and supporting patients in need. This decision may have a lasting impact on the sector and could change the landscape of the Canadian medical cannabis industry.

 


Disclaimer: Pursuant to an agreement between MAPH and Cannabis Wheaton (KWFLF) we were hired for 30 Days to publicly disseminate information about (KWFLF) including on the Website and other media including Facebook and Twitter. We are being paid $150,000 (CASH) for and were paid “0” shares of restricted common shares of Cannabis Wheaton. We may buy or sell additional shares of (KWFLF) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information.

0 9103

When We Connect the Dots, You Profit 
Connect the Dots Articles Have Returned 9,932% for Our Readers 

Over the last couple years, as the marijuana industry has taken flight, it has been our mission to help our readers make money from cannabis. Every once in a while we publish a “Connect the Dots” article highlighting a company or group of companies that we believe have tremendous near-term upside potential. By identifying these companies and providing insight and research otherwise unavailable to the mainstream investor, we have been able to help our readers gain as much as 9,932% in about two and a half years. That is the combined gain percentage that all of our Connect the Dots companies experienced in the weeks and months after we published an article. Let’s take a look at some of our biggest gainers:

*CannaGrow Holdings (CGRW); previously BizAuctions (BZCN) click here for article
Connect the Dots published on 10/8/14 at $0.053
CGRW hit $3.45 on 10/18/16
6,409% gain 

*Rocky Mountain High (RMHB); previously Totally Hemp Crazy (THCZ) click here for article
Connect the Dots published on 12/18/14 at $0.0115
THCZ hit $0.32 on 4/1/15
2,683% gain

*Future Farm Technologies (FFRMF); previously Arcturus Growthstar Technologies (AGSTF) click here for article
Connect the Dots published on 10/4/16 at $0.137
FFRMF hit $0.541 on 2/22/17
295% gain

*Vitality Biopharma (VBIO) click here for article
Connect the Dots published on 12/6/16 at $1.01
VBIO hit $4.24 on 12/27/16
320% gain

These are just a few of our previous Connect the Dots highlights. And as you can see, the track record speaks for itself. It is our goal to literally connect the dots for our readers to help identify opportunity in this budding industry. And thus far we have done more than just identify opportunity; we have helped some earn a small fortune.

Now we know it’s impossible to have captured all of the 9,932% gains. So let’s say you were able to capture just half. A $5,000 investment would be worth $248,300. Again, that’s if you only captured half of the total gains.

The marijuana industry is at a very interesting stage of its development right now. Even with nearly 10,000% gains in the books, we still feel that we’ve only seen the tip of the iceberg. And it’s one mighty iceberg. We hope that you are happy with the content we provide and continue to read our articles on a daily basis. Because you never know when the next cannabis opportunity will bud.


Pursuant to an agreement between MAPH and Future Farm Inc., we were hired for a period of 30 days to publicly disseminate information about (FFRMF) including on the Website and other media including Facebook and Twitter. We are being paid $37,500 (CASH) for and were paid 1 million shares of restricted common shares. We may buy or sell additional shares of (FFRMF) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information.Pursuant to an agreement between MAPH and a non affiliate third party, we were previously hired for a period of 30 days to publicly disseminate information about (VBIO) including on the Website and other media including Facebook and Twitter. We were paid $100,000 (CASH) for or were paid “ZERO” shares of unrestricted or restricted common shares. We own zero shares of (VBIO) which we purchased in the open market. We may buy or sell additional shares of (VBIO) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information.

0 5341

Although the Canadian cannabis sector offers tremendous upside, investors need to be cautious and focus on companies that have a differentiated strategy.

Back in the gold rush, the miners did not make all the money. It was the ancillary business who profited then and although times have changed, the opportunity has not. We believe that investors need to take a different approach and diversify around the Canadian licensed producers.

We have highlighted three Canadian cannabis stocks that trade in both the United States and Canada which we think have long-term upside due to their respective strategy.

InMed Starting to Catch Fire

InMed Pharmaceuticals Inc. (IMLFF) closed Friday down 5.3% but the shares ended the week up more than 12% off its lows and we think this is a stock investors need to watch. IMLFF broke below its 20 and 50-day moving average on this move lower and we think the shares are set to move higher as trading volume was well below its weekly average on Friday.

Earlier this month, InMed filed a provisional patent application in the United States for a cannabinoid-based topical therapy for glaucoma. The company has taken steps to execute on its strategy and has several event-driven catalysts set to occur in the back half of the year.

Cannabis Wheaton is Changing the Game

One company that looks to have found a bottom and is trending higher is Cannabis Wheaton (CBW.V) (KWFLF). The shares continued to rally on Friday and ended the day up 15% and 16%, respectively. The Canadian symbol is trading at $1.58 while the United States symbol, KWFLF trades at $1.16. Cannabis Wheaton has taken the licensed producer game to a different level and we believe there is significant value in several of its deals.

Earlier this month, Cannabis Wheaton released its roster of streaming deals and its partners include 14 companies based in six provinces across Canada. Of these companies, 2 have sales licenses (Broken Coast and Green Relief), 2 have cultivation licenses, 4 have affirmation letters and 6 are advanced pre-affirmation stage applicants.

Canadian Biotech Breaks Out of Oversold Territory and Set to Rally

Vinergy (VNNYF) traded almost 900,000 shares on Friday and VNNYF rallied well off its lows of the day. We think this massive increase in trading volume is significant and the shares no longer in oversold territory.

We see significant upside to current levels as VIN (the Canadian symbol) remains halted due to closing of the MJ Biopharma deal. Vinergy recently announced that it was increasing the size of its non-brokered private placement due to the high demand and this is a stock investors need to have on their radar

Disclaimer: Pursuant to an agreement between MAPH and InMedPharmaceuticals., we were hired for a period beginning February 24 2017 and ending April 24, 2017 to publicly disseminate information about (IMLFF) including on the Website and other media including Facebook and Twitter. We are being paid $40,000 (CASH) for and were paid “250,000” shares of restricted common shares of InMed Pharmaceuticals. Pursuant to an agreement between MAPH and Cannabis Wheaton (KWFLF) we were hired for 30 Days to publicly disseminate information about (KWFLF) including on the Website and other media including Facebook and Twitter. We are being paid $150,000 (CASH) for and were paid “0” shares of restricted common shares of Cannabis Wheaton. Pursuant to an agreement between MAPH and a non-affiliate third party, we were hired for a period of 1 month from 5/1/2017 – 6/1/2017 to publicly disseminate information about (VNNYF) including on the Website and other media including Facebook and Twitter. We are being paid $150,000 (CASH) for or “ZERO” shares of restricted or unrestricted common shares. We own zero shares of (VNNYF) which we purchased in the open market. We may buy or sell additional shares of (IMLFF, KWFLF, VNNYF) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information.

0 14246

Among the many segments of the marijuana industry that we cover, CBD has taken on a big role not only for its biotech-based applications but also for its uses outside of the health sciences sector. And with the growth that the market as a whole could be set to see, CBD companies are definitely in the spotlight for the foreseeable future.

One Marijuana Stock that we’ve been reporting on since late last year has been Ubiquitech Software Corp (UBQU).  Now don’t let the name fool you, this company, through its subsidiary HempLife Today™ is breaking barriers with its CBD brand while also hitting major milestones over the last year.  What could be best of all is that 2017 could already have the stage set for yet another record setting period in (UBQU)’s company history.

Earlier this morning the company put out preliminary guidance on what it is anticipating to be a banner year ahead.  According to the release, the company anticipates that revenues for the year ending November 30, 2017 will increase over 55% from $3,493,113, which was reported in the annual period ended November 30, 2016 to approximately $5,450,000.

Ubiquitech Gives Fiscal Year 2017 Revenue Guidance; Anticipates 55% Year Over Year Increase To $5,450,000

“We are very pleased with the progress we have made and we will continue to do everything within our power to keep our company relevant and growing” said James Ballas, CEO “With the quality of our products, our marketing, customer support and satisfaction, and our dynamic thinking, we will continue this growth through 2017 and into 2018, which we are already planning big things for, and this is the thinking that will take our revenues to even higher gains as we continue. It’s a very exciting industry and we don’t plan to stop until the CannazALL brand is a household word.”

(UBQU) is no stranger to growth.  If you’re just pulling up the company’s other headlines, you’ll already notice major strides being made on the product end. Toward the beginning of the year, the company announced that it had concluded negotiations and reached an agreement to expand its hemp growing capabilities through an additional 140 acres of available hemp operations. They’ve also expanded their current product line to include brand new offerings.

But back to growth…Had this been a random company with its first press release in history, we might be a bit skeptical but (UBQU) has already proven its ability to run a multi-million dollar business that has managed to grow significantly just within the last year alone. On top of bullish guidance for the year ahead, (UBQU) is also coming off of a strong year and noticeable earnings growth.

Revenues for the last quarter increased to $1,225,015 and to $3,493,113 for the year. But what’s more is that net income increased over 700% from the previous year to $334,350 from $39,651 in 2015. First quarter guidance has already come in bullish on its own with the company expecting revenues for the quarter ended February 28, 2017 to increase over 50% from $697,640 in the first quarter of last year to approximately $1,050,000.

Of course this is just initial guidance and with the year ahead, nothing is set in stone. But one thing is certain and that based on the last releases from the company, (UBQU) has set itself on a growth trend.  So this bullish guidance could be shedding some light on what’s to come for this company in the very near term.

The opportunity for taking advantage of the growth that CBD is beginning to see, could be important to take into consideration.  We’ve previously written about this market and how it could be on a path for growth.  Figures estimate that the CBD market will grow to a $2.1 billion market in sales by 2020. That’s a 700% increase from 2016.  Think about this for a moment: (UBQU) is already growing and is expecting to continue this growth to the tune of 50+% for the year according to today’s announcement…this is all going to happen during a time where the CBD industry as a whole is also anticipating significant growth. Having already come off of a banner year, we think that preliminary guidance from the company would suggest that this is something to be paying close attention to moving into the coming weeks/months/quarters.

Again, you can access today’s (UBQU) news here:

Ubiquitech Gives Fiscal Year 2017 Revenue Guidance; Anticipates 55% Year Over Year Increase To $5,450,000

Pursuant to an agreement between MAPH and Ubiquitech Software Corp., we were hired for a period beginning November 11 2016 and ending May 11, 2017 to publicly disseminate information about (UBQU) including on the Website and other media including Facebook and Twitter. We are being paid $0 (CASH) for or were paid “10 million” shares of restricted common shares. We may buy or sell additional shares of (UBQU) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Full Disclaimer Here

 

 

 

0 1626
marijuana

University Of Florida To Be Funded $2.5 Million For Medical Marijuana Research

 

A proposal that would award $2.5 million for UF to study medical marijuana recently moved forward in the Florida House of Representatives. The proposal states that money from the General Revenue Fund will be used to fund UF’s study on the safety and efficiency of medical cannabis. The bill, which passed through the Health Care Appropriations Subcommittee, moved into the Appropriations Committee on Friday.


Click Here Now To Read Full Article


 

Proposal In Nevada Aims To Loosen Cannabis Regulations

Senate Bill 329, introduced by Sen. Tick Segerblom, D-Las Vegas, would loosen some medical marijuana regulations, an idea Governor Brian Sandoval has stated his opposition to. Senate Bill 329 proposes a plethora of changes to how the state deals with cannabis. It would allow veterans to obtain a medical marijuana card, add PTSD to the list of conditions that qualify for those cards and even make it so cards do not need to be renewed. Medical cards now last 12 months in Nevada.


Click Here Now To Read Full Article


Lawmakers In West Virginia Look At Legalizing Industrial Hemp

 

Recently, Legislature sent separate proposals to the floor pushing for the legalization of commercial hemp production in West Virginia. Often, hemp is associated with marijuana. However, the new legislation declares hemp’s industrial uses. The bills state as long as the crop stays below a 1% threshold of tetrahydrocannabinol, the psychoactive component of cannabis, it can be produced after receiving licensing from the Agriculture Commissioner.


Click Here Now To Read Full Article


0 2006

DENVER, CO–(Mar 23, 2017) – Ubiquitech Software Corp. ( OTC PINK : UBQU ), through its operating subsidiary HempLifeToday.com, is announcing fiscal year 2017 revenue guidance.

The company anticipates that revenues for the year ending November 30, 2017 will increase over 55% from $3,493,113 reported in the year ago period to approximately $5,450,000.

The company is basing this guidance on the strong internal first quarter numbers and the continuance of that trend during March of this year. The company continues to gain increased exposure of its HempLife Today product line, develop new and improved products, and spread the word regarding the benefits of CBD Hemp derived products available and sold through its proprietary CBD brand CannazALL.

The company expects to give updates on its full year guidance in the coming months. The company sells and markets its line of high quality products through its web portal www.HempLifeToday.com.

“We are very pleased with the progress we have made and we will continue to do everything within our power to keep our company relevant and growing,” said James Ballas, CEO. “With the quality of our products, our marketing, customer support and satisfaction, and our dynamic thinking, we will continue this growth through 2017 and into 2018, which we are already planning big things for, and this is the thinking that will take our revenues to even higher gains as we continue. It’s a very exciting industry and we don’t plan to stop until the CannazALL brand is a household word.”

“With the wide footprint we have on the Internet and the amount of industry content about us that is also growing, we have the ability to grow while also protecting revenue,” adds Tim Zorn, President. “This allows us to strategically spend advertising dollars where we get the best results and is why our cost per customer acquisition is down by over 90% since last year. Steady sales and profitability is what we always strive for.”

The Company wants shareholders to know that it is moving forward on all plans released in previous press from 3.09.2017. This update is to inform shareholders of company progress and to keep shareholders informed of said progress.

About Ubiquitech (HempLife Today™)
Ubiquitech Software Corp, through its subsidiaries is a dynamic multi-media, multi-faceted corporation utilizing state-of-the-art global internet marketing, Direct Response (DRTV) Television, Radio, and traditional marketing, to drive traffic to the new and emerging multi-billion dollar industries like its subsidiary HempLifeToday.com™

HempLifeToday™ focuses on the exciting and dynamic new thinking in the world today that recognizes the important health and life enriching enhancement that CBD Oil from the Hemp plant can bring. Through its network of quality USA growers HempLifeToday.com™ has developed multiple and proprietary CannazALL™ CBD oil products that include; It’s popular CBD Tinctures, Oils, GelCaps, CBD Powder, Skin Salve, Wax Crumble, and e-liquid, all offered @ www.HempLifeToday.com

This press release contains forward-looking statements. Words such as “expects”, “intends”, “believes”, and similar expressions reflecting something other than historical fact are intended to identify forward-looking statements, but are not the exclusive means of identifying such statements. These forward-looking statements involve a number of risks and uncertainties, including the timely development and market acceptance of products and technologies, the ability to secure additional sources of finance, the ability to reduce operating expenses, and other factors described in the Company’s filings with the OTC Markets Group. The actual results that the Company achieves may differ materially from any forward-looking statement due to such risks and uncertainties. The Company undertakes no obligation to revise or update any forward-looking statements in order to reflect events or circumstances that may arise after the date of this release.

0 5849
Marijuana Stocks

Marijuana Stocks, especially Cannabis Companies with strong ties to Biotech have been increasingly front and center on Wall Street’s main stage.  Marijuana Stocks and the Cannabis-Biotech sector continue to evolve and grow into the mainstream powerhouse we know it can and will be. We have identified a small Cannabis-Biotech start up that deserves your attention.

InMed Pharmaceuticals (IMLFF) is a Vancouver-based pre-clinical trial Cannabis-Biotech company that has not only developed a proprietary cannabinoid manufacturing system yet in the process created a highly sought after database, which has mapped the different compounds of cannabinoids to the various diseases that it can address.

This cannabinoid database was designed by (IMLFF) to assist them in their investigative studies and has currently become a core asset as other Cannabis Biotech companies have come knocking on their door willing to offer a hefty sum for this information. Most medical marijuana processors are using THC and CBD because they are easy to extract in large quantities, however there are more than 90 diverse cannabinoid structures that (IMLFF) has plugged into its system. The bioinformatics algorithm has taken those different compounds and screens them against approved drugs, diseases and genetic properties of diseases. It then selects specific cannabinoids that might help regulate that particular disease.

InMed Pharmaceuticals (IMLFF) has created this database “tool” & is saving time and money in the drug research process. It has already helped (IMLFF) to identify two treatments for rare diseases. One for a rare children’s skin disease called epidermolysis bullosa (EB) that has no approved treatments and the other for glaucoma. Chief Executive Officer Eric Adams said, “It’s a very devastating disease and we found out in early testing that this set of cannabinoids treat the major symptoms of this disease giving them a tremendous amount of relief, but it may also reverse the disease, which is something no one has really talked about before.”

Startup Cannabis-Biotechs like InMed Pharmaceuticals (IMLFF) will continue to grow as Marijuana Stocks / Sector continues to evolve into mainstream markets.

Subscribe Now & Begin Receiving Marijuana Stocks News, Articles, Trade Alerts & MORE, all 100% FREE!

We are your #1 source for all things Marijuana Stocks, Subscribe Below!

Privacy Policy: We will NEVER share, sell, barter, etc. any of our subscribers information for any reason ever! By subscribing you agree we can send you via email our free e-newsletter on marijuana stocks related, articles, news and trade alerts. Further questions please contact privacy@marijuanastocks.com
Ad Placements